卵巣明細胞癌という癌は下に示すようにあまり予後の良くない癌らしい。(元来卵巣がんそのものの予後も不良なのだが)その明細胞癌の6割弱に変異が認められる遺伝子が見つかった。ARID1Aといってクロマチンのリモデリング関連遺伝子のようだ。6割とはは高頻度である。42例中24例で57%。ボーゲルシュタインのグループである。
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Siân Jones,1 Tian-Li Wang,2 Ie-Ming Shih,3 Tsui-Lien Mao,4 Kentaro Nakayama,5 Richard Roden,3 Ruth Glas,6 Dennis Slamon,6 Luis A. Diaz, Jr.,1 Bert Vogelstein,1 Kenneth W. Kinzler,1,* Victor E. Velculescu,1,* Nickolas Papadopoulos1,*
Ovarian clear cell carcinoma (OCCC) is an aggressive human cancer
that is generally resistant to therapy. To explore the genetic
origin of OCCC, we determined the exomic sequences of eight
tumors after immunoaffinity purification of cancer cells. Through
comparative analyses of normal cells from the same patients,
we identified four genes that were mutated in at least two tumors.
PIK3CA, which encodes a subunit of phosphatidylinositol-3 kinase,
and
KRAS, which encodes a well-known oncoprotein, had previously
been implicated in OCCC. The other two mutated genes were previously
unknown to be involved in OCCC:
PPP2R1A encodes a regulatory
subunit of serine/threonine phosphatase 2, and
ARID1A encodes
adenine-thymine (AT)–rich interactive domain–containing
protein 1A, which participates in chromatin remodeling. The
nature and pattern of the mutations suggest that
PPP2R1A functions
as an oncogene and
ARID1A as a tumor-suppressor gene. In a total
of 42 OCCCs, 7% had mutations in
PPP2R1A and 57% had mutations
in
ARID1A. These results suggest that aberrant chromatin remodeling
contributes to the pathogenesis of OCCC.
Originally published in Science Express on 8 September 2010 Science 8 October 2010:
Vol. 330. no. 6001, pp. 228 - 231
大阪医療センターHPからのデータ 表層上皮性卵巣がんの組織型別の治療成績(1993-95) 組織型 | 臨床進行期 |
l期 | ll期 | lll期 | lV期 |
例数 | 生存率 | 例数 | 生存率 | 例数 | 生存率 | 例数 | 生存率 |
漿液性腺がん | 427 | 89.4 | 153 | 65.4 | 1188 | 32.7 | 254 | 18.5 |
粘液性腺がん | 477 | 90.7 | 44 | 78.7 | 149 | 38.0 | 38 | 12.3 |
類内膜腺がん | 228 | 87.0 | 82 | 69.1 | 208 | 37.6 | 46 | 24.6 |
明細胞腺がん | 101 | 83.6 | 27 | 63.5 | 68 | 27.4 | 15 | 0 |
未分化腺がん | 56 | 81.0 | 19 | 49.8 | 103 | 29.8 | 40 | 0 |